Cardium Therapeutics, Inc. (CXM) Scheduled to Present at Biotech Showcase 2013 Investment Conference

Earlier this morning, Cardium Therapeutics announced that its CEO will be presenting at the Biotech Showcase 2013 Conference. This year the annual conference is being held January 7-9 at the Parc 55 Wyndham San Francisco Union Square Hotel. Cardium’s presentation will be available live and by replay. Those unable to attend will be able to access the executive presentation at

Cardium will provide a corporate overview as well as a review of its entrepreneurial initiatives, which include strategic partner-enabled product and platform opportunities that have been internally developed based on Cardium’s unique skill set, capabilities, and technology.

Current entrepreneurial initiatives include: (1) the clinical development of Genedexa™ (previously referred to as the Excellarate™ product candidate), a DNA-based Phase 2b/3 product candidate initially for the treatment of chronic, non-healing diabetic foot ulcers and representing the first product extension from Cardium’s FDA-cleared Excellagen® technology platform; (2) LifeAgain™, a medical analytics and e-commerce platform of algorithms and medical-based social media programs that were developed by Cardium researchers to support a strategically partnered commercialization of specialized survivable risk life insurance underwritings for cancer patients and patients with chronic medical diseases, based on the improvement of early diagnosis and new chronic treatments and curative medical therapies; and (3) plans to leverage the established infrastructure, distribution capabilities, and established retail network of To Go Brands® through internal product development, external product acquisitions, and strategic partnering.

In addition to the initiatives listed above, Cardium Therapeutics will continue to focus on its primary objectives that include: (1) the strategic partnering and commercialization of the FDA-cleared Excellagen® product and platform; and (2) the successful completion of the DNA-based Generx® Phase 3 development program. Information is provided in an updated investor presentation now available on Cardium’s website at

For more information on Cardium, visit

Please read full disclaimers at